Medicuba S. A. Pharmaceutical Import Profile — Cuba (DGFT 2022–2026)

Name: Medicuba S. A. Pharmaceutical Import Records from India — 2 Products, $108.0K FOB USD (DGFT 2022–2026)
Creator: TransData Nexus

Suresh Sormare

Explore

Medicuba S. A. — Pharmaceutical Importer Profile (2026) | 2 Products, $108.0K Trade | TransData Nexus

Medicuba S. A.

Pharmaceutical Importer · Cuba · Advanced Antibiotics Focus · $108.0K Total Trade · DGFT Verified

Medicuba S. A. is a pharmaceutical importer based in Cuba with a total trade value of $108.0K across 2 products in 2 therapeutic categories. Based on 4 verified import shipments from Indian Customs (DGFT) records, the company actively imports across multiple product segments. Medicuba S. A. sources from 1 verified Indian supplier, with S.d.pharmaceuticals accounting for 100.0% of imports.

Medicuba S. A. — Import Portfolio & Supplier Network

Medicuba S. A. import network — 2 products from Indian suppliers. Source: Indian Customs (DGFT).

Who Are the Verified Indian Suppliers to Medicuba S. A.?

Customs-verified supplier relationships from Indian DGFT records

Supplier	Value	Shipments	Share
S.d.pharmaceuticals	$123.5K	17	100.0%

Medicuba S. A. sources from 1 verified Indian supplier across 13 distinct formulations. The sourcing is highly concentrated — S.d.pharmaceuticals accounts for 100.0% of total imports, indicating a strategic single-source relationship.

What Formulations Does Medicuba S. A. Import?

Formulation	Value	Ships
Idarubicin hydrochloride for	$35.1K	2
Bicalutamide tablets 150MG(batch no & other detail as per inv & packing list)	$17.0K	3
Hydroxypropylmethycellulose + dextran	$12.6K	1
Cyclophosphamide for injection USP 1000MG (lyophilized) (batch no & other details as per inv & packing list)	$10.8K	2
Melphalan tablets 2MG (batch no & otherdetails as per inv & packing list)	$8.3K	1
Fluorometholone + tetrahydrozoline ophthalmic suspension 1MG + 0.25MG/ML (batchno & other detail as per inv & packing	$7.9K	1
Fluorometholone + tetrahydrozoline	$6.3K	1
Mitoxantrone hydrochloride injection 2MG/ML (batch no & other details as per inv& packing list)	$6.2K	1
Chlorambucil tablets BP 2MG (batch no &other detail as per inv & packing list)	$5.6K	1
Nimodipine intravenous infusion 200mcg/ML (batch no & other details as per inv& packing list)	$4.4K	1
Dactinomycin for injection 500mcg (lyophilized) (batch no & other details as perinv & packing list)	$4.2K	1
Clarithromycin for injection 500MG (lyophilized)(batch no & other details as perinv & packing list)	$3.3K	1
Mitoxantrone hydrochloride injection 2MG/ML (batch no & other details as per inv& packing list)	$1.8K	1

Import Portfolio — Top 2 by Import Value

#	Product	Category	Value	Ships	Share	Rk
1	Teicoplanin	Advanced Antibiotics	$100.0K	2	1.6%	2
2	Mitoxantrone	Advanced Oncology	$8.0K	2	0.4%	6

Medicuba S. A. imports 2 pharmaceutical products across 2 categories into Cuba totaling $108.0K.

Medicuba S. A. — Corporate Profile & Information

Company type, headquarters, distribution network, and industry role

1Company Overview

Medicuba S.A. is a state-owned enterprise established in December 1962, dedicated to the import and export of medical products, including medicines, reagents, diagnostics, surgical instruments, and medical technology. Headquartered in Havana, Cuba, at Calle 2 No. 352 e/ 15 y 17, the company plays a pivotal role in supplying the Cuban National Health System and its international medical collaboration missions. (en.granma.cu)

As a government procurement entity, Medicuba S.A. ensures the availability of essential medical supplies across Cuba's healthcare facilities. The company's operations encompass the procurement of a diverse range of medical products, including parenteral solutions, vaccines, immunoglobulins, reagents, and various medical equipment. (en.granma.cu)

2Distribution Network

While specific details about Medicuba S.A.'s warehouse locations and logistics capabilities are not publicly disclosed, the company's extensive import activities suggest a well-established distribution network. The enterprise's operations are designed to effectively supply the National Health System and support Cuba's medical services abroad. (en.granma.cu)

3Industry Role

Medicuba S.A. functions as a primary wholesaler and government procurement entity within Cuba's pharmaceutical supply chain. By importing and distributing a wide array of medical products, the company ensures that healthcare facilities across the nation have access to necessary medications and medical equipment. Additionally, Medicuba S.A. supports Cuba's international medical collaboration missions, highlighting its significant role in both domestic and international healthcare provisioning. (en.granma.cu)

TransData Nexus Research · Company registries, industry databasesMar 2026

Supplier Relationship Intelligence — Medicuba S. A.

Sourcing concentration, supply chain resilience, and strategic implications

1Sourcing Concentration Analysis

Medicuba S.A.'s sourcing strategy exhibits a high degree of concentration, with a total import value of $108,000 USD from India across four shipments, all supplied by S.D. Pharmaceuticals. This single-source dependency indicates a strategic choice to maintain a consistent supply chain and potentially leverage favorable terms with a trusted supplier. The stability of this relationship is evidenced by the consistent importation of two products—Teicoplanin and Mitoxantrone—across two therapeutic categories, suggesting a reliable and ongoing partnership.

2Supply Chain Resilience

The resilience of Medicuba S.A.'s Indian supply chain appears robust, given the consistent sourcing from a single supplier, S.D. Pharmaceuticals. However, the lack of backup suppliers introduces a potential risk in the event of supply disruptions. The diversity of formulations imported—13 unique formulations—indicates a strategic approach to meet various therapeutic needs. While the single-supplier model offers stability, it also underscores the importance of ensuring the supplier's operational continuity and compliance with international quality standards.

3Strategic Implications

Importing Pharmaceuticals into Cuba — Regulatory Framework

Regulatory authority, GMP requirements, import licensing for Cuba

1Regulatory Authority & Framework

In Cuba, the Ministry of Public Health (MINSAP) serves as the primary regulatory authority overseeing the importation of medical products. The licensing system for medicines, medical equipment, and devices is designed to prevent the commercial importation of products that are of questionable quality or efficacy, or that have been adulterated or tampered with. This system ensures that imported medical products meet the health and safety standards required for use within the Cuban healthcare system.

2Import Licensing & GMP

Import licensing requirements in Cuba are governed by MINSAP, which implements a non-automatic licensing regime for medicines, medical equipment, and devices. This system aims to prevent the importation of products that may pose health risks due to quality issues. While specific details about the recognition of Good Manufacturing Practice (GMP) certificates are not explicitly stated, it is implied that imported products must comply with recognized international standards to ensure safety and efficacy.

3Quality & Labeling

Medicuba S. A. — Procurement Pattern Analysis

Product strategy, sourcing profile, and market positioning

1Product Strategy

Medicuba S.A.'s focus on importing advanced antibiotics and oncology medications aligns with the therapeutic needs of Cuba's healthcare system. The substantial import value of Teicoplanin ($100,000 USD) and Mitoxantrone ($8,000 USD) indicates a strategic emphasis on these critical therapeutic areas. This focus is likely driven by the prevalence of infections and cancer cases within the Cuban population, necessitating a reliable supply of these specialized treatments.

2Sourcing Profile

Medicuba S.A. employs a sourcing strategy that prioritizes high-quality, finished pharmaceutical formulations from a single supplier, S.D. Pharmaceuticals in India. This approach ensures consistency and reliability in the supply chain, particularly for advanced antibiotics and oncology medications. The importation of 13 unique formulations reflects a tailored approach to meet the diverse therapeutic needs of the Cuban healthcare system.

3Market Positioning

Based on its product mix, Medicuba S.A. serves the hospital and government tender segments of the Cuban market. The importation of specialized medications such as Teicoplanin and Mitoxantrone suggests a focus on providing essential treatments for complex medical conditions within these settings. By ensuring a steady supply of these critical medications, Medicuba S.A. supports the delivery of advanced healthcare services across the nation.

Seller's Guide — How to Become a Supplier to Medicuba S. A.

Opportunity assessment, qualifications, and practical approach strategy

1Opportunity Assessment

There is a realistic opportunity for new Indian suppliers to engage with Medicuba S.A., provided they can meet the stringent quality and regulatory standards required by the Cuban market. Diversifying the supplier base could offer Medicuba S.A. more flexibility and security in its supply chain, potentially mitigating risks associated with single-source dependency. For Indian exporters, establishing relationships with Medicuba S.A. could open avenues for supplying a range of pharmaceutical products to the Cuban market, especially in therapeutic areas where there is a demand for specialized treatments.

2Requirements & Qualifications

Indian exporters seeking to supply Medicuba S.A. must ensure that their products comply with the quality and safety standards mandated by MINSAP. This includes adherence to recognized international GMP standards, proper labeling, and necessary certifications. Additionally, exporters should be prepared to navigate Cuba's import licensing procedures, which aim to prevent the importation of substandard or counterfeit medical products.

3How to Approach

Frequently Asked Questions — Medicuba S. A.

What products does Medicuba S. A. import from India?

Medicuba S. A. imports 2 pharmaceutical products across 2 categories. Top imports: Teicoplanin ($100.0K), Mitoxantrone ($8.0K).

Who supplies pharmaceuticals to Medicuba S. A. from India?

Medicuba S. A. sources from 1 verified Indian suppliers. The primary supplier is S.d.pharmaceuticals (100.0% of imports, $123.5K).

What is Medicuba S. A.'s total pharmaceutical import value?

Medicuba S. A.'s total pharmaceutical import value from India is $108.0K, based on 4 verified shipments in Indian Customs (DGFT) data.

What therapeutic categories does Medicuba S. A. focus on?

Medicuba S. A. imports across 2 categories. The largest: Advanced Antibiotics (92.6%), Advanced Oncology (7.4%).

Get Full Medicuba S. A. Import Intelligence

Access shipment-level details, supplier connections, pricing data, and competitive analysis. TransData Nexus provides verified Indian Customs (DGFT) data trusted by pharmaceutical trade professionals worldwide.

Contact for Data Access Request Live Demo

Official References & Regulatory Resources

Verify import regulations and drug registration requirements with the agencies above.

Research Methodology & Data Transparency

Suresh Sormare

Verified Author

Pharmaceutical Export-Import Analyst & Trade Intelligence Expert

Suresh Sormare is a pharmaceutical export-import analyst with deep expertise in Indian Customs (DGFT) data, HS code classification, and global pharmaceutical supply chains. His analysis covers 10M+ shipment records across 150+ countries and is used by manufacturers, procurement agencies, and trade consultants worldwide. Suresh specializes in identifying verified suppliers and buyers from customs records, mapping bilateral pharmaceutical trade corridors, analyzing tariff structures and regulatory frameworks across 170+ destination markets, and benchmarking competitive positioning for finished pharmaceutical formulations. His methodology combines granular customs transaction data with regulatory intelligence from FDA, EMA, WHO, CDSCO, and 40+ national drug authorities to deliver actionable trade insights for the pharmaceutical formulations sector.

linkedin.com/in/sureshsormare

Primary Data Source

All trade data is sourced from Indian Customs (DGFT) official shipping bill records — the authoritative government database for India's pharmaceutical trade. Each verified record contains exporter name, consignee (buyer) name, detailed product description, quantity, declared FOB value (USD), port of loading, destination country, and shipment date.

Data Source & Methodology

Trade data sourced from Indian Customs (DGFT) export shipment records. Values represent FOB export value in USD. Profile aggregates 2 company name variants from customs records. For current shipment-level data, contact TransData Nexus.